ClinicalTrials.gov
public full text
Public Domain
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
This is a single-arm, multicentre real-world observational study of TAS-102 in combination with regorafenib or fruquintinib for third-line and above advanced colorectal cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer#152414
- A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.#847384
- Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC#841575
- First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer#217038
- A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment#1124430
Record · ID 837004
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive